Diagnosis and Treatment of Acquired Aplastic Anemia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 2, 2009, Pages 159-170

  Bacigalupo, Andrea ^a   Passweg, Jakob ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antithymocyte globulin; Bone marrow failure; Cyclosporine; Growth factors; Hemopoietic stem cell transplantation

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNIZATION; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FANCONI ANEMIA; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT CARE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SURVIVAL RATE;

AGE FACTORS; ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FEMALE; FETAL BLOOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PREGNANCY; PROGNOSIS;

EID: 62649106211     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.01.005     Document Type: Review

References (43)

1. Bagby G.C., and Alter B.P. Fanconi anemia. Semin Hematol 43 3 (2006) 147-156 Review
2. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 (2006) 1233-1243
3. Luzzatto L., Bessler M., and Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?. Cell 88 (1997) 1-4
4. Sugimori C., Chuhjo T., Feng X., et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 (2006) 1308-1314
5. Bean M.A., Graham T., Appelbaum F.R., et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation 57 3 (1994) 423-426
6. Young N.S., Calado R.T., and Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 (2006) 2509-2519
7. Bacigalupo A., Chaple M., Hows J., et al. Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol 83 (1993) 145-151
8. Locasciulli A., Oneto R., Bacigalupo A., et al., Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92 (2007) 11-18
9. Bacigalupo A., Brand R., Oneto R., et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy: the European Group for Blood and Marrow Transplantation experience. Semin Hematol 37 (2000) 69-80
10. Camitta B., O'Reilly R.J., Sensenbrenner L., et al. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 62 (1983) 883-888
11. Frickhofen N., Heimpel H., Kaltwasser G.P., et al. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101 (2003) 1236-1242
12. Viollier R., Passweg J., Gregor M., et al. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol 84 (2005) 47-55
13. Bacigalupo A., Bruno B., Saracco P., et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 95 (2000) 1931-1934
14. Kojima S., Frickhofen N., Deeg H.J., et al. Aplastic anemia. Int J Hematol 82 (2005) 408-411
15. Di Bona E., Rodeghiero F., Bruno B., et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol 107 (1999) 330-334
16. Saracco P., Quarello P., Iori A.P., et al., Bone Marrow Failure Study Group of the AIEOP (Italian Association of Paediatric Haematology Oncology). Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 140 (2008) 197-205
17. Schrezenmeier H., Marin P., Ragavachar A., et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. for the EBMT SAA Working Party. Br J Haematol 85 (1993) 371-377
18. Teramura M., Kimura A., Iwase S., et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 110 6 (2007) 1756-1761
19. Tichelli A., Passweg J., Nissen C., et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 100 (1998) 393-400
20. Gluckman E., Rokicka-Milewska R., Hann I., et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 119 (2002) 1075-1082
21. Socie G., Mary J.Y., Schrezenmeier H., et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and marrow Transplantation (EBMT). Blood 109 (2007) 2794-2796
22. Ohara A., Kojima S., Hamajima N., et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 90 (1997) 1009-1013
23. Locasciulli A., Bruno B., Rambaldi A., et al. Treatment of severe aplastic anemia with anti-lymphocyte globulin, cyclosporine and two different granulocyte colony stimulating factor regimens: a GITMO prospective randomized study. Haematologica 89 (2004) 1054-1061
24. Sociè G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 329 (1993) 1152-1157
25. Kojima S., Matsuyama T., Kato S., et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 100 (2002) 799-803
26. Bacigalupo A., Hows J., Gluckman E., et al. Bone marrow transplantation (BMT) versus immunosuppression (IS) for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 70 (1988) 177-181
27. Tichelli A., Socié G., Henry-Amar M., et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 130 (1999) 193-201
28. Tichelli A., Socié G., Marsh J., et al., for the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med 137 (2002) 164-172
29. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia: a report from the European Group for blood and marrow transplantation and the Center for International blood and marrow transplant research. Blood 110 4 (2007) 1397-1400
30. Niederwieser D., Pepe M., Storb R., et al. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. Br J Haematol 69 (1988) 23-28
31. Storb R., Leisenring W., Anasetti C., et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antitymocyte globulin. Blood 89 (1997) 3890-3891
32. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109 (2007) 4582-4585
33. Locatelli F., Bruno B., Zecca M., et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96 (2000) 1690-1697
34. George B., Methews V., Viswabandya A., et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant 40 1 (2007) 13-18
35. Srinivasan R., Takahashi Y., McCoy J.P., et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 133 3 (2006) 305-309
36. Resnick I.B., Aker M., Shapira M.Y., et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol 133 6 (2006) 649-653
37. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10 (1999) 1293-1299
38. Maury S., Balere-Appert M.L., Chir Z., et al. French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 92 (2007) 589-596
39. Viollier R., Socié G., Tichelli A., et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 41 1 (2008) 45-50
40. Deeg H.J., Amylon I.D., Harris R.E., et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7 (2001) 208-215
41. Bacigalupo A., Locatelli F., Lanino E., et al., Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 36 (2005) 947-950
42. Gluckman E., and Rocha V. History of the clinical use of umbilical cord blood hematopoietic cells. Cytotherapy 7 3 (2005) 219-227
43. Yoshimi A., Kojima S., Taniguchi S., et al. Japan Cord Blood Bank Network. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 14 9 (2008) 1057-1063